Baidu
map

CHMP建议批准拜耳regorafenib用于转移性结直肠癌(mCRC)治疗

2013-07-03 tomato 生物谷

拜耳(Bayer)上周末宣布,药物regorafenib获得了欧盟委员会(EC)人用医药产品委员会(CHMP)的积极意见。CHMP建议批准将regorafenib用于既往治疗过或不适用于当前可用疗法(包括基于氟尿嘧啶的化疗,抗VEGF疗法、抗EGFR疗法)的转移性结直肠癌(mCRC)成人患者的治疗。预计EC将于2013年第三季度作出审查决定。 CHMP的积极意见,是基于关键性III期CORREC

拜耳(Bayer)上周末宣布,药物regorafenib获得了欧盟委员会(EC)人用医药产品委员会(CHMP)的积极意见。CHMP建议批准将regorafenib用于既往治疗过或不适用于当前可用疗法(包括基于氟尿嘧啶的化疗,抗VEGF疗法、抗EGFR疗法)的转移性结直肠癌(mCRC)成人患者的治疗。预计EC将于2013年第三季度作出审查决定。

CHMP的积极意见,是基于关键性III期CORRECT临床试验数据,结果表明,与安慰剂相比,regorafenib显著延长了总生存期(OS),并显著延缓了癌症的进展。

Regorafenib是首个也是唯一一种在转移性结直肠癌(mCRC)中表现出总生存期益处的多激酶抑制剂。

Regorafenib品牌名为Stivarga,已获包括美国及日本在内的一些国家批准,用于mCRC的治疗,同时该药于今年2月获FDA批准用于胃肠道间质瘤(GIST)的治疗。

英文原文:Bayer AG : Bayer’s Regorafenib Recommended for Approval in the European Union for the Treatment of Metastatic Colorectal Cancer

Regorafenib shown in a pivotal Phase III trial to extend overall survival in patients with metastatic colorectal cancer (mCRC) whose disease had progressed after previous treatments

Berlin, June 28, 2013- Bayer's oncology compound regorafenib has been recommended for approval by the European Committee for Medicinal Products for Human Use (CHMP) treatment of adult patients with metastatic colorectal cancer (CRC) who have been previously treated with, or are not considered candidates for, available therapies. These include fluoropyrimidine based chemotherapy, an anti VEGF therapy and an anti EGFR therapy. The decision of the European Commission on the approval is expected in the third quarter of 2013.

"The recommendation by the CHMP for regorafenib is an important milestone for Bayer and brings us one step closer to providing an innovative new treatment option for patients with metastatic colorectal cancer," said Kemal Malik, MD, Member of the Bayer HealthCare Executive Committee and Head of Global Development. "Bayer is committed to developing new therapies in difficult-to-treat diseases like mCRC where there continues to be an unmet medical need for additional treatments, and we are delighted that regorafenib provides a potential new treatment option for patients and their physicians."

"The medical community constantly strives to find new and better treatment options in the fight against cancer. There are currently limited choices in mCRC so the potential approval of regorafenib in Europe can give patients and physicians new hope," said Eric Van Cutsem, Lead CORRECT investigator, University Hospital Gasthuisberg Leuven, Belgium. "In the pivotal Phase III CORRECT trial, regorafenib has been shown to prolong overall survival and slow the progression of cancer in patients whose disease had progressed after treatment with currently available therapies. It is the first and only multikinase inhibitor to show an overall survival benefit in mCRC and we are very encouraged by the positive opinion from CHMP."

The CHMP recommendation was based on data from the pivotal Phase III CORRECT (Colorectal cancer treated withregorafenib or placebo after failure of standardtherapy) trial. The study results showed that regorafenib plus BSC significantly improved both overall survival (OS) (HR=0.77, 1-sided p-value=0.0052) and progression-free survival (PFS) (HR=0.49, 1-sided p-value <0.000001) compared to placebo plus BSC in patients with mCRC whose disease had progressed after approved standard therapies. In the study, median OS was 6.4 months with regorafenib versus 5.0 months with placebo; median PFS was 1.9 months with regorafenib versus 1.7 months with placebo.

In the CORRECT study, the most frequently observed adverse drug reactions (equally or greater than 30%) in patients receiving regorafenib were asthenia/fatigue, decreased appetite and food intake, hand-foot-skin reaction/ palmar-plantar erythrodysesthesia, diarrhea, mucositis, weight loss, infection, hypertension, and dysphonia. In regorafenib clinical trials the most serious adverse drug reactions in patients receiving regorafenib were hepatotoxicity, hemorrhage and gastrointestinal perforation.

Full results from the CORRECT study were presented at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO) in June 2012 and published in the journal The Lancet in January 2013.

Regorafenib is approved under the brand name Stivarga® in several countries, including the USA and Japan, for the treatment of mCRC. It has also received U.S. approval for the treatment of patients with gastrointestinal stromal tumors (GIST) in February 2013. The NDA for regorafenib for the treatment of GIST filed in Japan in December 2012 was granted priority review.

{nextpage}

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1642733, encodeId=6b421642e3316, content=<a href='/topic/show?id=b70711396cd' target=_blank style='color:#2F92EE;'>#mCRC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11396, encryptionId=b70711396cd, topicName=mCRC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8c9723008141, createdName=LShY0906_98743851, createdTime=Sat Oct 26 01:03:00 CST 2013, time=2013-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827223, encodeId=50e2182e2234e, content=<a href='/topic/show?id=52e95194b9' target=_blank style='color:#2F92EE;'>#CRC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5194, encryptionId=52e95194b9, topicName=CRC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Thu Jul 18 09:03:00 CST 2013, time=2013-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302606, encodeId=d8a81302606d7, content=<a href='/topic/show?id=1b6846653e' target=_blank style='color:#2F92EE;'>#CHMP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4665, encryptionId=1b6846653e, topicName=CHMP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b505306, createdName=医生2394, createdTime=Fri Jul 05 13:03:00 CST 2013, time=2013-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318409, encodeId=d6ff1318409b9, content=<a href='/topic/show?id=9a535625968' target=_blank style='color:#2F92EE;'>#拜耳#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56259, encryptionId=9a535625968, topicName=拜耳)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=11b4465, createdName=ying_wu, createdTime=Fri Jul 05 13:03:00 CST 2013, time=2013-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386097, encodeId=e117138609ea7, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Fri Jul 05 13:03:00 CST 2013, time=2013-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452633, encodeId=8fe81452633e2, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Fri Jul 05 13:03:00 CST 2013, time=2013-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1553743, encodeId=4e9e1553e437c, content=<a href='/topic/show?id=e96a15280ee' target=_blank style='color:#2F92EE;'>#Regorafenib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15280, encryptionId=e96a15280ee, topicName=Regorafenib)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=04aa14409774, createdName=yilong5287547, createdTime=Fri Jul 05 13:03:00 CST 2013, time=2013-07-05, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1642733, encodeId=6b421642e3316, content=<a href='/topic/show?id=b70711396cd' target=_blank style='color:#2F92EE;'>#mCRC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11396, encryptionId=b70711396cd, topicName=mCRC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8c9723008141, createdName=LShY0906_98743851, createdTime=Sat Oct 26 01:03:00 CST 2013, time=2013-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827223, encodeId=50e2182e2234e, content=<a href='/topic/show?id=52e95194b9' target=_blank style='color:#2F92EE;'>#CRC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5194, encryptionId=52e95194b9, topicName=CRC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Thu Jul 18 09:03:00 CST 2013, time=2013-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302606, encodeId=d8a81302606d7, content=<a href='/topic/show?id=1b6846653e' target=_blank style='color:#2F92EE;'>#CHMP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4665, encryptionId=1b6846653e, topicName=CHMP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b505306, createdName=医生2394, createdTime=Fri Jul 05 13:03:00 CST 2013, time=2013-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318409, encodeId=d6ff1318409b9, content=<a href='/topic/show?id=9a535625968' target=_blank style='color:#2F92EE;'>#拜耳#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56259, encryptionId=9a535625968, topicName=拜耳)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=11b4465, createdName=ying_wu, createdTime=Fri Jul 05 13:03:00 CST 2013, time=2013-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386097, encodeId=e117138609ea7, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Fri Jul 05 13:03:00 CST 2013, time=2013-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452633, encodeId=8fe81452633e2, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Fri Jul 05 13:03:00 CST 2013, time=2013-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1553743, encodeId=4e9e1553e437c, content=<a href='/topic/show?id=e96a15280ee' target=_blank style='color:#2F92EE;'>#Regorafenib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15280, encryptionId=e96a15280ee, topicName=Regorafenib)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=04aa14409774, createdName=yilong5287547, createdTime=Fri Jul 05 13:03:00 CST 2013, time=2013-07-05, status=1, ipAttribution=)]
    2013-07-18 yxch36
  3. [GetPortalCommentsPageByObjectIdResponse(id=1642733, encodeId=6b421642e3316, content=<a href='/topic/show?id=b70711396cd' target=_blank style='color:#2F92EE;'>#mCRC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11396, encryptionId=b70711396cd, topicName=mCRC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8c9723008141, createdName=LShY0906_98743851, createdTime=Sat Oct 26 01:03:00 CST 2013, time=2013-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827223, encodeId=50e2182e2234e, content=<a href='/topic/show?id=52e95194b9' target=_blank style='color:#2F92EE;'>#CRC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5194, encryptionId=52e95194b9, topicName=CRC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Thu Jul 18 09:03:00 CST 2013, time=2013-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302606, encodeId=d8a81302606d7, content=<a href='/topic/show?id=1b6846653e' target=_blank style='color:#2F92EE;'>#CHMP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4665, encryptionId=1b6846653e, topicName=CHMP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b505306, createdName=医生2394, createdTime=Fri Jul 05 13:03:00 CST 2013, time=2013-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318409, encodeId=d6ff1318409b9, content=<a href='/topic/show?id=9a535625968' target=_blank style='color:#2F92EE;'>#拜耳#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56259, encryptionId=9a535625968, topicName=拜耳)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=11b4465, createdName=ying_wu, createdTime=Fri Jul 05 13:03:00 CST 2013, time=2013-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386097, encodeId=e117138609ea7, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Fri Jul 05 13:03:00 CST 2013, time=2013-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452633, encodeId=8fe81452633e2, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Fri Jul 05 13:03:00 CST 2013, time=2013-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1553743, encodeId=4e9e1553e437c, content=<a href='/topic/show?id=e96a15280ee' target=_blank style='color:#2F92EE;'>#Regorafenib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15280, encryptionId=e96a15280ee, topicName=Regorafenib)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=04aa14409774, createdName=yilong5287547, createdTime=Fri Jul 05 13:03:00 CST 2013, time=2013-07-05, status=1, ipAttribution=)]
    2013-07-05 医生2394
  4. [GetPortalCommentsPageByObjectIdResponse(id=1642733, encodeId=6b421642e3316, content=<a href='/topic/show?id=b70711396cd' target=_blank style='color:#2F92EE;'>#mCRC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11396, encryptionId=b70711396cd, topicName=mCRC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8c9723008141, createdName=LShY0906_98743851, createdTime=Sat Oct 26 01:03:00 CST 2013, time=2013-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827223, encodeId=50e2182e2234e, content=<a href='/topic/show?id=52e95194b9' target=_blank style='color:#2F92EE;'>#CRC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5194, encryptionId=52e95194b9, topicName=CRC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Thu Jul 18 09:03:00 CST 2013, time=2013-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302606, encodeId=d8a81302606d7, content=<a href='/topic/show?id=1b6846653e' target=_blank style='color:#2F92EE;'>#CHMP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4665, encryptionId=1b6846653e, topicName=CHMP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b505306, createdName=医生2394, createdTime=Fri Jul 05 13:03:00 CST 2013, time=2013-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318409, encodeId=d6ff1318409b9, content=<a href='/topic/show?id=9a535625968' target=_blank style='color:#2F92EE;'>#拜耳#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56259, encryptionId=9a535625968, topicName=拜耳)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=11b4465, createdName=ying_wu, createdTime=Fri Jul 05 13:03:00 CST 2013, time=2013-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386097, encodeId=e117138609ea7, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Fri Jul 05 13:03:00 CST 2013, time=2013-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452633, encodeId=8fe81452633e2, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Fri Jul 05 13:03:00 CST 2013, time=2013-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1553743, encodeId=4e9e1553e437c, content=<a href='/topic/show?id=e96a15280ee' target=_blank style='color:#2F92EE;'>#Regorafenib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15280, encryptionId=e96a15280ee, topicName=Regorafenib)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=04aa14409774, createdName=yilong5287547, createdTime=Fri Jul 05 13:03:00 CST 2013, time=2013-07-05, status=1, ipAttribution=)]
    2013-07-05 ying_wu
  5. [GetPortalCommentsPageByObjectIdResponse(id=1642733, encodeId=6b421642e3316, content=<a href='/topic/show?id=b70711396cd' target=_blank style='color:#2F92EE;'>#mCRC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11396, encryptionId=b70711396cd, topicName=mCRC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8c9723008141, createdName=LShY0906_98743851, createdTime=Sat Oct 26 01:03:00 CST 2013, time=2013-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827223, encodeId=50e2182e2234e, content=<a href='/topic/show?id=52e95194b9' target=_blank style='color:#2F92EE;'>#CRC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5194, encryptionId=52e95194b9, topicName=CRC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Thu Jul 18 09:03:00 CST 2013, time=2013-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302606, encodeId=d8a81302606d7, content=<a href='/topic/show?id=1b6846653e' target=_blank style='color:#2F92EE;'>#CHMP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4665, encryptionId=1b6846653e, topicName=CHMP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b505306, createdName=医生2394, createdTime=Fri Jul 05 13:03:00 CST 2013, time=2013-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318409, encodeId=d6ff1318409b9, content=<a href='/topic/show?id=9a535625968' target=_blank style='color:#2F92EE;'>#拜耳#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56259, encryptionId=9a535625968, topicName=拜耳)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=11b4465, createdName=ying_wu, createdTime=Fri Jul 05 13:03:00 CST 2013, time=2013-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386097, encodeId=e117138609ea7, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Fri Jul 05 13:03:00 CST 2013, time=2013-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452633, encodeId=8fe81452633e2, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Fri Jul 05 13:03:00 CST 2013, time=2013-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1553743, encodeId=4e9e1553e437c, content=<a href='/topic/show?id=e96a15280ee' target=_blank style='color:#2F92EE;'>#Regorafenib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15280, encryptionId=e96a15280ee, topicName=Regorafenib)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=04aa14409774, createdName=yilong5287547, createdTime=Fri Jul 05 13:03:00 CST 2013, time=2013-07-05, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1642733, encodeId=6b421642e3316, content=<a href='/topic/show?id=b70711396cd' target=_blank style='color:#2F92EE;'>#mCRC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11396, encryptionId=b70711396cd, topicName=mCRC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8c9723008141, createdName=LShY0906_98743851, createdTime=Sat Oct 26 01:03:00 CST 2013, time=2013-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827223, encodeId=50e2182e2234e, content=<a href='/topic/show?id=52e95194b9' target=_blank style='color:#2F92EE;'>#CRC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5194, encryptionId=52e95194b9, topicName=CRC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Thu Jul 18 09:03:00 CST 2013, time=2013-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302606, encodeId=d8a81302606d7, content=<a href='/topic/show?id=1b6846653e' target=_blank style='color:#2F92EE;'>#CHMP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4665, encryptionId=1b6846653e, topicName=CHMP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b505306, createdName=医生2394, createdTime=Fri Jul 05 13:03:00 CST 2013, time=2013-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318409, encodeId=d6ff1318409b9, content=<a href='/topic/show?id=9a535625968' target=_blank style='color:#2F92EE;'>#拜耳#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56259, encryptionId=9a535625968, topicName=拜耳)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=11b4465, createdName=ying_wu, createdTime=Fri Jul 05 13:03:00 CST 2013, time=2013-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386097, encodeId=e117138609ea7, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Fri Jul 05 13:03:00 CST 2013, time=2013-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452633, encodeId=8fe81452633e2, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Fri Jul 05 13:03:00 CST 2013, time=2013-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1553743, encodeId=4e9e1553e437c, content=<a href='/topic/show?id=e96a15280ee' target=_blank style='color:#2F92EE;'>#Regorafenib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15280, encryptionId=e96a15280ee, topicName=Regorafenib)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=04aa14409774, createdName=yilong5287547, createdTime=Fri Jul 05 13:03:00 CST 2013, time=2013-07-05, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1642733, encodeId=6b421642e3316, content=<a href='/topic/show?id=b70711396cd' target=_blank style='color:#2F92EE;'>#mCRC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11396, encryptionId=b70711396cd, topicName=mCRC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8c9723008141, createdName=LShY0906_98743851, createdTime=Sat Oct 26 01:03:00 CST 2013, time=2013-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827223, encodeId=50e2182e2234e, content=<a href='/topic/show?id=52e95194b9' target=_blank style='color:#2F92EE;'>#CRC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5194, encryptionId=52e95194b9, topicName=CRC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Thu Jul 18 09:03:00 CST 2013, time=2013-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302606, encodeId=d8a81302606d7, content=<a href='/topic/show?id=1b6846653e' target=_blank style='color:#2F92EE;'>#CHMP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4665, encryptionId=1b6846653e, topicName=CHMP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b505306, createdName=医生2394, createdTime=Fri Jul 05 13:03:00 CST 2013, time=2013-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318409, encodeId=d6ff1318409b9, content=<a href='/topic/show?id=9a535625968' target=_blank style='color:#2F92EE;'>#拜耳#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56259, encryptionId=9a535625968, topicName=拜耳)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=11b4465, createdName=ying_wu, createdTime=Fri Jul 05 13:03:00 CST 2013, time=2013-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386097, encodeId=e117138609ea7, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Fri Jul 05 13:03:00 CST 2013, time=2013-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452633, encodeId=8fe81452633e2, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Fri Jul 05 13:03:00 CST 2013, time=2013-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1553743, encodeId=4e9e1553e437c, content=<a href='/topic/show?id=e96a15280ee' target=_blank style='color:#2F92EE;'>#Regorafenib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15280, encryptionId=e96a15280ee, topicName=Regorafenib)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=04aa14409774, createdName=yilong5287547, createdTime=Fri Jul 05 13:03:00 CST 2013, time=2013-07-05, status=1, ipAttribution=)]

相关资讯

FDA批准Regorafenib治疗转移性结直肠癌

  Regorafenib是一种口服多激酶抑制剂,9月27日,美国食品与药物管理局(FDA)宣布,已批准将其用于治疗转移性结直肠癌。批准的适应证为治疗转移性结直肠癌患者,“这些患者之前已接受氟嘧啶、奥沙利铂和伊立替康为基础的化疗、1种抗VEGF治疗,此外,如为KRAS野生型,已接受1种抗EGFR治疗。”   经由FDA针对重大治疗进展或无充分治疗疾病的新药的审查程序,Regorafenib在生产

FDA批准瑞格非尼治疗晚期胃肠间质肿瘤

  2013年2月25日,美国食品与药物管理局(FDA)通过优先审查程序扩大了瑞格非尼(regorafenib)的适应证,用于治疗不能手术和其他治疗手段无效的晚期胃肠间质肿瘤(regorafenib)的患者。   瑞格非尼是FDA批准的第三个用于治疗GIST的药物,其余两种药物分别为伊马替尼(imatinib)和舒尼替尼(sunitinib)。   一项纳入199例手术或其他治疗无

ASCO2013:国立台湾大学Ann-Lii Cheng将开展Regorafenib治疗进展期肝细胞癌3期试验

背景: 索拉非尼用于HCC一线全身性治疗已被广为接受,但对于接受索拉非尼治疗后进展期患者目前尚无标准的治疗选择。一项开放标签2期研究提示多激酶抑制剂REG具有可接受的安全性能,且显示出对于进展期HCC患者的抗癌活性的证据(Bolondi et al. Eur J Cancer 2011; 47 [Suppl 1]: abstract 6.576):病例对照设置为26/36例患者(72%),中位肿瘤

ASCO2013:regorafenib治疗TKI抵抗性GIST效果不受KIT基因突变状态的影响

背景:III 期GRID研究显示REG治疗至少经伊马替尼(IM)和舒尼替尼治疗失败的晚期胃肠道间质瘤(GIST) 相较于安慰剂可显著性改善患者无进展生存期(PFS) (SU; HR 0.27, p<0.0001)。由于肿瘤生长的异质性,明确TKI难治性GIST基因型是一项具有挑战性的任务,而且患者对连续接受一系列的活检也表现出抵触。为克服上述难题,研究者以血浆游离DNA为样本分析肿瘤DNA,

Baidu
map
Baidu
map
Baidu
map